Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma

17Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Osteoprotegerin (OPG) is a member of the tumor necrosis factor receptor superfamily of proteins. Although initial data illustrated the key role that OPG plays in bone turnover, numerous recent reports indicate that OPG is also an important factor in inflammatory pathways and tumor cell survival. OPG contributes directly to inflammatory processes and has been evaluated as a novel non-invasive biomarker of gut inflammation. Furthermore, OPG affects cell turn-over, differentiation, death, and survival via extracellular pathways, correlating with worse prognosis in inflammatory bowel diseases and several gastrointestinal carcinomas. It is now clear that OPG has multiple functions and characteristics. This review gives an overview of OPG, highlights its roles in different extracellular pathways, and outlines how OPG could be used as a novel non-invasive biological marker in inflammatory bowel diseases and gastrointestinal carcinomas.

Cite

CITATION STYLE

APA

De Voogd, F. A. E., Gearry, R. B., Mulder, C. J., & Day, A. S. (2016, August 1). Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma. Journal of Gastroenterology and Hepatology (Australia). Blackwell Publishing. https://doi.org/10.1111/jgh.13324

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free